Nucala Special Precautions

NUCALA should not be used to treat acute asthma exacerbations.
Asthma-related adverse events or exacerbations may occur during treatment with NUCALA. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.
Abrupt discontinuation of corticosteroids after initiation of NUCALA therapy is not recommended. Reductions in corticosteroid doses, if required, should be gradual and performed under the supervision of a physician.
Hypersensitivity and Administration Reactions: Acute and delayed systemic reactions, including hypersensitivity reactions (e.g. anaphylaxis, urticaria, angioedema, rash, bronchospasm, hypotension), have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances had a delayed onset (i.e., days).
Parasitic Infections: Eosinophils may be involved in the immunological response to some helminth infections. Patients with pre-existing helminth infections were excluded from participation in the clinical programme. Patients with pre-existing helminth infections should be treated for their infection prior to NUCALA therapy. If patients become infected whilst receiving treatment with NUCALA and do not respond to anti-helminth treatment, temporary discontinuation of NUCALA should be considered.
Effects on Ability to Drive and Use Machines: There have been no studies to investigate the effect of mepolizumab on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the pharmacology or adverse reaction profile of NUCALA.